Results 31 to 40 of about 54,797 (163)
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
International Journal of Clinical Practice, 2002 SUMMARYThe clinical properties (efficacy and safety profile) of a medicine are related not only to its mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are also influenced by its pharmacokinetic properties (absorption, distribution, metabolism and elimination).
J D, Corbin, S H, Francis
openaire +2 more sources
Phosphodiesterase 4 regulates pyroptosis in subarachnoid hemorrhage
Neural Regeneration ResearchPhosphodiesterase 4 is a key enzyme involved in the regulation of cell signal transduction, but its role in subarachnoid hemorrhage remains unclear. Neuronal pyroptosis has been reported to be involved in early brain injury after subarachnoid hemorrhage.
Jiahe Tan +5 more
doaj +1 more source
Photosensitive neurons in mollusks [PDF]
Archives of Biological Sciences, 2005 In addition to regular photoreceptors, some invertebrates possess simple extra ocular photoreceptors. For example, the central ganglia of mollusks contain photosensitive neurons.
Kartelija Gordana +2 more
doaj +1 more source
Clinics, 2011 OBJECTIVES: We investigated the influence of sildenafil on cardiac contractility and diastolic relaxation and examined the distribution of phosphodiesterase-5 in the hearts of hypertensive rats that were treated with by NG-nitro-L-arginine methyl ester ...
Silvia Elaine Ferreira-Melo +5 more
doaj +1 more source
Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Tiwari, Amit K., Chen, Zhe-Sheng
openaire +3 more sources
CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION
Евразийский Кардиологический Журнал, 2015 The patient with the verified diagnosis of idiopathic pulmonary hypertension, negative acute vasoreactivity testing by RHC, functional class III (WHO) was treated by phosphodiesterase type 5 inhibitor sildenafil.
Z. S. Valieva +5 more
doaj +1 more source
PLoS ONE, 2013 ObjectiveThe specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
Florian Rieder +5 more
doaj +1 more source
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
Drug Design, Development and Therapy, 2010 Mark A Giembycz1, Stephen K Field2Departments of 1Physiology and Pharmacology and 2Medicine, Airway Inflammation Research Group, Faculty of Medicine, University of Calgary, Alberta, CanadaAbstract: In April 2010, the European Medicines Agency Committee ...
Mark A Giembycz, Stephen K Field
doaj
Surface Binding Energy Landscapes Affect Phosphodiesterase Isoform-Specific Inhibitor Selectivity
Computational and Structural Biotechnology Journal, 2019 As human phosphodiesterase (PDE) proteins are attractive drug targets, a large number of selective PDE inhibitors have been developed. However, since the catalytic sites of PDE isoforms are conserved in sequence and structure, it remains unclear how ...
Qing Liu, Andreas Herrmann, Qiang Huang
doaj +1 more source
Characterization of Forskolin-Induced Ca2+ Signals in Rat Olfactory Receptor Neurons
Journal of Pharmacological Sciences, 2005 Forskolin-induced Ca2+ signals were examined in isolated rat olfactory receptor neurons (ORNs) using a Ca2+ indicator, fura-2. In the soma of the ORNs, forskolin caused an increase in the intracellular Ca2+ concentration ([Ca2+]i) that was enhanced by a ...
Ken-ichi Otsuguro +4 more
doaj +1 more source